CHICAGO, July 22 /PRNewswire-FirstCall/ -- Research presented at the American Association for Clinical Chemistry (AACC) annual meeting today indicates that monitoring cardiac transplant patients with the Urine NGAL assay on Abbott's ARCHITECT immunoassay analyzer may help clinicians to monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to prevent possible irreversible kidney damage.
In a scientific poster presented at AACC today by researchers at the University of Toronto, eleven heart transplant patients were treated with anti-rejection drug combinations and monitored with the Urine NGAL assay within twelve hours of administration. The study concluded that Urine NGAL monitoring may be able to assist in the detection of chronic cyclosporine-induced toxicity in the kidneys following heart transplant procedures.
Abbott is currently developing an assay to measure NGAL (neutrophil gelatinase-associated lipocalin) concentrations in urine for use on the company's flagship automated laboratory instrument, the ARCHITECT system. Abbott has rights to commercialize Urine NGAL for renal diagnostic applications and is expected to introduce the product in Europe in late 2009. The assay is not available in the United States. NGAL is a small, robust protein produced by the kidney tubules and appears in urine just two-to-four hours following acute kidney injury (AKI), up to 46 hours sooner than current test methods.
"Nephrologists and cardiologists are excited about the potential of Urine NGAL to detect the potential for kidney failure following cardio-thoracic surgeries," said Sudarshan Hebbar, M.D., medical director, Abbott Diagnostics.
About Abbott's Diagnostics Businesses
Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, referen
Copyright©2009 PR Newswire.
All rights reserved